The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 343:750-758 September 14, 2000 Number 11
NextNext

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
Richard Childs, M.D., Allen Chernoff, M.D., Nathalie Contentin, M.D., Erkut Bahceci, M.D., David Schrump, M.D., Susan Leitman, M.D., Elizabeth J. Read, M.D., John Tisdale, M.D., Cynthia Dunbar, M.D., W. Marston Linehan, M.D., Neal S. Young, M.D., and A. John Barrett, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Slavin, S.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Since allogeneic stem-cell transplantation can induce curative graft-versus-leukemia reactions in patients with hematologic cancers, we sought to induce analogous graft-versus-tumor effects in patients with metastatic renal-cell carcinoma by means of nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Methods Nineteen consecutive patients with refractory metastatic renal-cell carcinoma who had suitable donors received a preparative regimen of cyclophosphamide and fludarabine, followed by an infusion of a peripheral-blood stem-cell allograft from an HLA-identical sibling or a sibling with a mismatch of a single HLA antigen. Cyclosporine, used to prevent graft-versus-host disease, was withdrawn early in patients with mixed T-cell chimerism or disease progression. Patients with no response received up to three infusions of donor lymphocytes.

Results At the time of the last follow-up, 9 of the 19 patients were alive 287 to 831 days after transplantation (median follow-up, 402 days). Two had died of transplantation-related causes, and eight from progressive disease. In 10 patients (53 percent) metastatic disease regressed; 3 had a complete response, and 7 had a partial response. The patients who had a complete response remained in remission 27, 25, and 16 months after transplantation. Regression of metastases was delayed, occurring a median of 129 days after transplantation, and often followed the withdrawal of cyclosporine and the establishment of complete donor–T-cell chimerism. These results are consistent with a graft-versus-tumor effect.

Conclusions Nonmyeloablative allogeneic stem-cell transplantation can induce sustained regression of metastatic renal-cell carcinoma in patients who have had no response to conventional immunotherapy.


Source Information

From the Hematology Branch, National Heart, Lung, and Blood Institute (R.C., N.C., E.B., C.D., N.S.Y., A.J.B.); the Urologic Oncology Branch (A.C., W.M.L.) and the Surgery Branch (D.S.), Division of Clinical Sciences, National Cancer Institute; the Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center (S.L., E.J.R.), and the Molecular and Clinical Hematology Branch (J.T.), National Institute of Diabetes and Digestive and Kidney Diseases — all at the National Institutes of Health, Bethesda, Md. Other authors were Emmanuel Clave, Ph.D., Diane Epperson, Ph.D., and Virginia Mayo, R.N., Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.

Address reprint requests to Dr. Childs at the Hematology Branch, NHLBI/NIH, 10/7C103, 10 Center Dr., M.S.C. 1652, Bethesda, MD 20892-1652, or at childsr{at}nih.gov.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.